Jorge Lima de Magalhães
Biographic Data
| ID | 8532887 |
|---|---|
| NAME | Jorge Lima de Magalhães |
| GIVEN NAMES | Jorge Lima |
| FAMILY NAME | de Magalhães |
| SIGNATURE | DE MAGALHÃES J L |
| AFFILIATIONS | Universidade Federal do Rio de Janeiro |
| ORCID | 0000-0003-2219-5446 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2011 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Estudo comparativo das produções científicas e tecnológicas dos especialistas seniores em Covid-19 após um ano de pandemia no Brasil
A pandemia da Covid-19 mostrou-se como um dos maiores desafios sanitários de todos os tempos. Em tempos de crises e pandemias, o Big Data surge como uma ferramenta benéfica e essencial tanto do ponto de vista econômico quanto científico, especialmente no cenário no qual nos encontramos: ausência de medicamentos com eficácia clinicamente comprovada contra o novo vírus. Nesse contexto, torna-se cada vez mais importante o trabalho em rede, o compart…
The public production of medicines in Brazil
The paper aims to contribute as a reflection on the public production of medicines in Brazil. Public producers present themselves as strategic in Brazil, either as price regulators, in meeting the demands of the Ministry of Health (MoH) on neglected products and those at risk of shortage to SUS. The study used the official bases of the MoH, National Health Surveillance Agency (ANVISA) and Website of Official Pharmaceutical Laboratories (OPL). Thi…
The Official pharmaceutical laboratories and their relevance to Brazil’s public health
This paper identifies the current portfolio of the Brazilian Network for the Public Production of Medicines (RBPPM) and evaluates the modernization and expansion of the Official Pharmaceutical Laboratories (OPLs) production capacity in the last seven years. Investments of about R$ 300 million have been made to expand the annual installed capacity from 5 to 16.6 billion Pharmaceutical Units 1 (PUs). The work consisted of interviews, literature sea…
Laboratórios farmacêuticos oficiais e sua relevância para saúde pública do Brasil
This paper identifies the current portfolio of the Brazilian Network for the Public Production of Medicines (RBPPM) and evaluates the modernization and expansion of the Official Pharmaceutical Laboratories (OPLs) production capacity in the last seven years. Investments of about R$ 300 million have been made to expand the annual installed capacity from 5 to 16.6 billion Pharmaceutical Units 1 (PUs). The work consisted of interviews, literature sea…
No prominent works on this page.
The Official pharmaceutical laboratories and their relevance to Brazil’s public health
This paper identifies the current portfolio of the Brazilian Network for the Public Production of Medicines (RBPPM) and evaluates the modernization and expansion of the Official Pharmaceutical Laboratories (OPLs) production capacity in the last seven years. Investments of about R$ 300 million have been made to expand the annual installed capacity from 5 to 16.6 billion Pharmaceutical Units 1 (PUs). The work consisted of interviews, literature sea…
Laboratórios farmacêuticos oficiais e sua relevância para saúde pública do Brasil
This paper identifies the current portfolio of the Brazilian Network for the Public Production of Medicines (RBPPM) and evaluates the modernization and expansion of the Official Pharmaceutical Laboratories (OPLs) production capacity in the last seven years. Investments of about R$ 300 million have been made to expand the annual installed capacity from 5 to 16.6 billion Pharmaceutical Units 1 (PUs). The work consisted of interviews, literature sea…
The public production of medicines in Brazil
The paper aims to contribute as a reflection on the public production of medicines in Brazil. Public producers present themselves as strategic in Brazil, either as price regulators, in meeting the demands of the Ministry of Health (MoH) on neglected products and those at risk of shortage to SUS. The study used the official bases of the MoH, National Health Surveillance Agency (ANVISA) and Website of Official Pharmaceutical Laboratories (OPL). Thi…
Estudo comparativo das produções científicas e tecnológicas dos especialistas seniores em Covid-19 após um ano de pandemia no Brasil
A pandemia da Covid-19 mostrou-se como um dos maiores desafios sanitários de todos os tempos. Em tempos de crises e pandemias, o Big Data surge como uma ferramenta benéfica e essencial tanto do ponto de vista econômico quanto científico, especialmente no cenário no qual nos encontramos: ausência de medicamentos com eficácia clinicamente comprovada contra o novo vírus. Nesse contexto, torna-se cada vez mais importante o trabalho em rede, o compart…
Medicine (4 works) · Political science (4 works) · Business (3 works) · Christian ministry (3 works) · Finance (3 works) · Portfolio (3 works) · Public Health in Brazil (3 works) · Economic growth (2 works) · Economics (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works)